Cipla Gears Up for Q3 Reveal on 23rd January; Check Key Expectations Here

Name: Stock Advisory service In India
Brand: univest
Rating: 4.4 (197000 reviews)

Posted by : sachet | Thu Jan 22 2026

Cipla Gears Up for Q3 Reveal on 23rd January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results

Cipla’s Q3 results FY26 are scheduled to be announced on 23rd January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

Cipla Q3 Results 2026 Preview

Cipla’s revenue is expected to be in the range of ₹7,072.97 crore, a 0.13% YoY increase.
Profit After Tax, or PAT, is projected to rise by 20.57% YoY.
Cipla’s EBITDA is expected to rise to ₹1,709.12 crore.
Net profit is ₹1,570.51 crore, up 20.57% YoY

Cipla Share Performance

Over the past six months, Cipla’s share price has fallen by 5.80% to ₹1,379.30.
Moreover, over the past year, the stock has increased by 4.22%.
Despite this weak short-term performance, Cipla’s stock has delivered a financially sound 70.57% return over the past 5 years.
As of 22nd January 2026, the stock traded at ₹1,379.30 per share.

Key Factors to Watch for Cipla Q3 Results FY26

Domestic and International Sales Trends: Growth in India and emerging markets versus performance in the U.S. market, especially given past pressures on U.S. sales and price erosion issues.
Product Mix & Pipeline Launches: Updates on key launches (e.g., Lanreotide normalisation, Abraxane/Advair timelines) and approvals that could drive future revenue.
Margins & Cost Structure: Impact of product mix, pricing pressures, and operating leverage on EBITDA and net margins.
Regulatory and Supply Chain Factors: Any commentary on supply disruptions, regulatory approvals, and site compliance matters affecting production and U.S. market access.

Final Thoughts

Cipla will announce its Q3 FY26 results on 23rd January 2026. Analysts expect 0.13% YoY revenue growth, a 20.57% rise in PAT, and a 5.90% rise in EBITDA. Cipla focuses on strengthening its India and emerging markets business, improving profitability through a better product mix, scaling its respiratory and complex generics portfolio, and driving growth via new launches and regulatory approvals in key markets.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!